LambdaVision is developing the first protein-based artificial retina to restore meaningful vision for patients who are blind or have lost significant sight due to advanced retinal degenerative diseases, including retinitis pigmentosa (RP) and age-related macular degeneration (AMD).

Both RP and AMD lead to the breakdown and loss of cells in the retina. By using proteins similar to the visual pigment rhodopsin that is naturally found in our eyes, LambdaVision’s protein-based artificial retina mimics the light-absorbing properties of human photoreceptors replacing the function of these damaged cells in the retinas of blind patients.